Status:
COMPLETED
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Squamous Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva...
Eligibility Criteria
Inclusion
- Adult patients, \>/=18 years of age
- Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV)
- Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start
Exclusion
- Not agreeing to be followed-up (for a maximum of 24 months)
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT01488331
Start Date
June 1 2010
End Date
November 1 2013
Last Update
November 2 2016
Active Locations (92)
Enter a location and click search to find clinical trials sorted by distance.
1
Abbeville, France, 80142
2
Agen, France, 47000
3
Aix-en-Provence, France, 13616
4
Aix-en-Provence, France, 13617